Related Experiment Video
Updated: Jan 18, 2026
Gastric Mucosa Quantitative Polymerase Chain Reaction Analysis for Detecting Helicobacter pylori and Antibiotic Resistance
Published on: March 7, 2025
Practical Efficacy of a 1-Week Metronidazole-Based Triple Regimen Plus Bismuth Versus a 2-Week Bismuth-Based
Kyeong Ah Jang1, Keun Young Maeng2, Dong Seok Lee1
1Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Objective:
For patients with clarithromycin-resistant Helicobacter pylori infection, a 2-week bismuth quadruple therapy (2W-PBMT) is typically recommended. However, a recent Korean guideline suggests a 1-week metronidazole-based regimen (PMA) as an alternative. This study aimed to evaluate whether a 1-week PMA plus bismuth (1W-PBMA) could achieve comparable efficacy to the conventional 2W-PBMT.
Methods:
This study retrospectively analyzed medical records from two academic hospitals and employed propensity score matching (PSM) to minimize confounding variables.
Results:
A total of 121 patients with confirmed H. pylori infection and clarithromycin resistance-related genetic mutations were identified via polymerase chain reaction. After excluding six patients with the A2142G mutation, 115 patients with the A2143G mutation were enrolled. Among them, 82 patients who received an eradication regimen were included in the final analysis. Fifty-one patients received the conventional 2W-PBMT, while 31 received the 1W-PBMA regimen. PSM resulted in 25 matched cases in each group. Before PSM, eradication rates were 70.6% (2W-PBMT) vs. 77.4% (1W-PBMA) in the intention-to-treat (ITT) analysis and 94.7% vs. 85.7% in the per-protocol (PP) analysis, with no significant differences. After PSM, ITT eradication rates were 68.0% (2W-PBMT) vs. 80.0% (1W-PBMA), while PP eradication rates were 94.4% vs. 87.0%, again showing no statistical significance. Medication adherence exceeded 85% in both groups, with comparable incidences of adverse events. However, the 2W-PBMT group had a slightly higher discontinuation rate due to intolerable side effects.
Conclusions:
In patients with H. pylori infection harboring the A2143G point mutation, the 1W-PBMA regimen demonstrated comparable eradication efficacy to the 2W-PBMT regimen, with potentially fewer intolerable adverse effects and improved adherence.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:23Gastritis III: Clinical Manifestations and Management
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...